




EASL CONGRESS

7-10 May 2025

Amsterdam, the Netherlands



List of accepted **late-breaker** abstracts

#EASLCongress

easlcongress.eu



LB25106

Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements

Poster presentation

Presenter: Andrada Seicean

LB25112

Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)

Oral presentation

Presenter: Mazen Nouredin

LB25115

Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study

Poster presentation

Presenter: Jidong Jia

LB25119

SCG101 HBV-specific TCR-T cell therapy demonstrates dual antiviral and antitumor activities, achieving HBV clearance in liver biopsies and functional cure in HBV-related hepatocellular carcinoma patients

Poster presentation

Presenter: Shunda Du

LB25123

Chronic hepatitis B virus infected participants responding to prior BRIL-179 treatment achieved faster and higher rate of hepatitis B virus surface antigen seroclearance on elebsiran plus peginterferon-alfa: end of treatment data from ENSURE study

Poster presentation

Presenter: Grace Lai-Hung Wong

LB25145

Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo

Poster presentation

Presenter: Mary E. Rinella

LB25148

Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial

Oral presentation

Presenter: Michael Trauner

LB25153

Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)

Poster presentation
Presenter: Grace Lai-Hung Wong

LB25161

Prolonged reduction of hepatitis B surface antigen in virologically suppressed participants treated with concurrent or sequential use of pegylated interferon alpha with xalnesiran-based therapy: results after 120 weeks of follow-up of an observational study

Poster presentation
Presenter: Xieer Liang

LB25162

Treatment options to support the elimination of hepatitis C: an open label, factorial randomised controlled trial

Poster presentation
Presenter: Graham S Cooke

LB25168

Validation of quantitative magnetic resonance cholangiopancreatography metrics in the prediction of event-free survival in primary sclerosing cholangitis: an International PSC study group collaboration

Poster presentation
Presenter: Tim Middelburg

LB2517

DA-1241, a GPR119 agonist, demonstrates hepatoprotective and glucose-regulating effects in a 16-week randomized placebo-controlled trial in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients

Poster presentation
Presenter: Rohit Loomba

LB25182

Metabolic dysfunction- and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort

Poster presentation
Presenter: Zobair Younossi

LB25183

Belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension: results from the NAVIGATE trial

Oral presentation
Presenter: Naim Alkhouri

LB252

Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D

Poster presentation
Presenter: Marc P. Windisch

LB2520

MELD 3.i: a bayesian approach for consecutive updates to model for end-stage liver disease

Poster presentation

Presenter: Tomohiro Tanaka

LB25201

Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis: results of the pivotal phase 3 GLISTEN trial

Oral presentation

Presenter: Gideon M. Hirschfield

LB25202

Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis: Proteomic results from the ELATIVE® trial

Poster presentation

Presenter: Mark Swain

LB2521

Macrophage Nrf1-Foxo1 axis controls liver fibrosis by modulation of mitochondrial reprogramming

Poster presentation

Presenter: Qiong Wu

LB25217

Excess waitlist mortality and transplant benefit for patients with severe acute-on-chronic liver failure: results of the CHANCE study

Poster presentation

Presenter: Thierry Gustot

LB25220

Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis, with limited correlation with pruritus: analyses from the phase III ELATIVE® trial

Poster presentation

Presenter: David E. Jones

LB25221

Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up

Oral presentation

Presenter: Heiner Wedemeyer

LB25222

Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial

Oral presentation

Presenter: Cynthia Levy

LB25228

Variceal hemorrhage outcomes are worse in patients with prior decompensating events. Systematic review with individual patient data meta-analysis

Poster presentation

Presenter: Vincenzo La Mura

LB25237

Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC

Poster presentation

Presenter: Marta Piqué-Gili

LB25242

Pitfalls in creatinine measurement and their impact on model for end stage liver disease score

Poster presentation

Presenter: Eda Kaya

LB25246

Advancing prime editing for Wilson disease: precise and durable in vivo Correction of ATP7B mutations

Poster presentation

Presenter: mohammed asmal

LB25251

Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline

Poster presentation

Presenter: Karl Heinz Weiss

LB25259

Liver transplantation after downstaging of intermediate and advanced HCC with atezolizumab-bevacizumab: a prospective study (ImmunoXXL)

Oral presentation

Presenter: Sherrie Bhoori

LB25263

Rapid HBsAg declines and HBsAb seroconversion observed with a single dose of VRON-0200 plus Tobeivart and Elebsiran: preliminary results of a VRON-0200 combination treatment from a phase 1b study for functional cure in chronically HBV-infected patients

Poster presentation

Presenter: Edward J. Gane

LB25270

Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients

Poster presentation

Presenter: Filippo Gabrielli

LB25276

Addition of triple biomarkers and/or GALAD score to ultrasound enhances the sensitivity of HCC surveillance: a multi-centre randomised controlled trial

Poster presentation

Presenter: Supot Nimanong

LB25282

Suboptimal performances of Baveno VII and AASLD 2024 criteria for detecting clinically significant portal hypertension with varices in untreated patients with HDV cirrhosis

Poster presentation

Presenter: Maria Paola Anolli

LB25306

Initial safety data from ELIMINATE-B, the first clinical trial of a gene editing treatment for chronic hepatitis B

Poster presentation

Presenter: Alina Jucov

LB2542

Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507

Poster presentation

Presenter: Man-Fung Yuen

LB255

High-throughput combinatorial CRISPR screening in hepatic progenitor cell-derived organoids reveals genetic determinants of response to standard-of-care chemotherapy in cholangiocarcinoma

Poster presentation

Presenter: Michael Girma Mamo

LB2553

High prevalence of undiagnosed liver fibrosis in the adult european population driven by metabolic risk factors and alcohol consumption. results from the prospective liverscreen cohort in 30,541 subjects

Oral presentation

Presenter: Isabel Graupera

LB2554

Globally derived and externally validated cut offs for liver failure and inclusion of infections improve prognostication for inpatient death: towards ACLF harmonization

Poster presentation

Presenter: Jasmohan Bajaj

LB2556

Short-term intravenous albumin administration increases serum sodium levels in hospitalized patients with decompensated cirrhosis and dilutional hyponatremia. A randomized, multicenter, controlled trial (ALBUCAT)

Poster presentation

Presenter: Adrià Juanola

LB2559

Modeling the epidemic of metabolic dysfunction associated steatohepatitis in Europe shows a growing clinical and economic burden in France, Italy and United Kingdom

Poster presentation

Presenter: Zobair Younossi

LB2567

Multicenter, open-Label, randomized non-inferiority study comparing 8-week vs 12-week Sofosbuvir/Ravidasvir treatment for non-cirrhotic chronic hepatitis C patients (EASE trial)

Poster presentation

Presenter: Muhammad Radzi bin Abu Hassan

LB257

DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebo-controlled, do

Poster presentation

Presenter: Yongliang Fang

LB2582

Novel hepatitis B virus biomarkers-guided nucleos(t)ide analogues withdrawal strategy promotes hepatitis B surface antigen clearance in chronic hepatitis B patients: results from a randomized controlled trial (BIO-STOP study)

Poster presentation

Presenter: Rui Deng

LB2586

HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb study

Poster presentation

Presenter: Junqi Niu

LB259

Primary analysis of a phase 2b open-label study demonstrates VTP-300 administered with low-dose nivolumab is associated with meaningful reductions of HBsAg in chronic hepatitis B participants with HBsAg less than 200 IU/mL

Poster presentation

Presenter: Man-Fung Yuen

LB2591

Efficacy and safety of long-term human albumin therapy in cirrhotic patients with acute decompensation and ascites: top-line results of the PRECIOSA trial

Oral presentation

Presenter: Javier Fernández

LB2593

Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis

Oral presentation

Presenter: Naim Alkhouri